

Ecully, September 29, 2025 – 6:00 p.m.

SpineWay celebrates 20 years of innovation in spine surgery

The SpineWay Group, a specialist in innovative implants and instruments for the treatment of severe spine disorders, is celebrating its 20th anniversary this year. Throughout its history, the company has demonstrated an unwavering commitment to innovation and offering surgeons more effective technologies to improve quality of life for patients in France and around the world.



Twenty years of defining development

In two decades, the Lyon-based company, founded in September 2005, has succeeded in establishing itself alongside the major players in the sector. Starting out with a very small team, the Group now employs more than 50 people, markets its product ranges in over 40 countries worldwide and has already contributed to the success of over 100,000 surgical procedures. Focused on international export since its creation, SpineWay has forged key international partnerships with both distributors and surgeons. From the beginning, SpineWay has positioned itself as a key partner for surgeons, developing technical solutions that meet their needs and keep pace with technological developments.

Key milestones include an initial public offering on Euronext Growth (formerly Alternext) in 2013 and strategic acquisitions – Distimp in 2021 and Spine Innovations in 2022 – which brought together three complementary entities around a shared vision: to develop and market innovative implants and instruments to improve spine surgery and patient care.

A forward-looking Group

SpineWay is now a key player in the sector and has solid fundamentals to support its vision. Through [SpineWay Academy](#), its international training program in surgical techniques, the Group has consolidated its position as a trusted partner for spine surgeons, training over 700 practitioners in Europe, Latin America, and Asia in just three years.

With nearly €12 million in revenue in 2024, the Group is enjoying positive momentum in 2025, with further improvement in its half-year results and a strengthening of its financial position.¹ Additionally, its new production unit dedicated to LP-ESP and CP-ESP disc prostheses, located in France, is a strategic asset that will support its growth and manufacturing quality in the coming years.²

Spineway is entering a new stage in its development, and intends to transform its industrial, commercial, and medical advances into levers for sustainable growth. This will help consolidate its position as a leading partner in the treatment of spine disorders. **Its ambition remains clear: to become a major player in spine care by leveraging its expertise, its capacity for innovation, the commitment of its teams, and the safety and performance of its products.**

"Celebrating Spineway's 20th anniversary means celebrating a human and technological adventure driven by innovation and a commitment to patient care. We owe our success above all to our teams, our partner surgeons, and our shareholders, who have supported us over the years. Together, we have built an innovative, recognized, and forward-looking company. These two decades have reinforced our ambition to continue growing and consolidating our position among the major players in the European spine market by offering surgeons high-performance solutions adapted to developments in spine surgery," said Spineway CEO Stéphane Le Roux.

Next event:

October 14, 2025 – Q3 2025 revenue

About Spineway

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.

Spineway has an international network of over 50 independent distributors and more than 70% of its revenue comes from exports.



Spineway is eligible for the PEA-PME (equity savings plans for SMEs)



Listing venue: **Euronext Growth Paris**

ISIN: **FR001400N2P2**

Ticker: **ALSPW**

Find out all about Spineway at www.spineway.com

¹ Press release of July 30, 2025

² Press release of July 3, 2025

Contacts:



Spineway

Shareholder-services line

Available Tuesday through Thursday (10 a.m.-12 midday)
08 06 70 60 60



Aelium

Investor relations

Solène Kennis

spineway@aelium.fr

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.